IL1R1 and melanoma: The NLRP3 inflammasome shows different levels of pathway activation according to disease stage: it is constitutively activated in late stages of melanoma, producing high levels of IL-1β in the microenvironment [152,153], while IL-1β secretion has been found to require the activation of the receptor IL-1R during intermediate stage cancer in vitro [153].